NEW YORK (360Dx) – Quidel announced after the close of the market on Monday changes to its reporting segments.

During the fourth quarter, the company changed its presentation of revenue to "reflect how management strategically thinks about the business categories," it said in a statement. Revenues for the QuickVue and Sofia businesses will be reported within Quidel's immunoassay category, while Solana AmpliVue, and Lyra products will be reported in its molecular category.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.